Julian Wolfson

Learn More
BACKGROUND The sieve analysis for the Step trial found evidence that breakthrough HIV-1 sequences for MRKAd5/HIV-1 Gag/Pol/Nef vaccine recipients were more divergent from the vaccine insert than placebo sequences in regions with predicted epitopes. We linked the viral sequence data with immune response and acute viral load data to explore mechanisms for and(More)
Given a randomized treatment Z, a clinical outcome Y, and a biomarker S measured some fixed time after Z is administered, we may be interested in addressing the surrogate endpoint problem by evaluating whether S can be used to reliably predict the effect of Z on Y. Several recent proposals for the statistical evaluation of surrogate value have been based on(More)
In vaccine research, immune biomarkers that can reliably predict a vaccine's effect on the clinical endpoint (i.e., surrogate markers) are important tools for guiding vaccine development. This article addresses issues on optimizing two-phase sampling study design for evaluating surrogate markers in a principal surrogate framework, motivated by the design of(More)
(2010). Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification. (2012). High-throughput assessment of transgene copy number in sugarcane using real-time quantitative PCR. Evaluation of techniques for generation of single-stranded DNA for quantitative detection.based amplification(More)
Note: References to equation numbers in the main manuscript are preceded by M, eg. η i (β L (s + ∆s)) = η i (β L (s)) + ∂η i ∂β (β L (s))(β L (s + ∆s) − β L (s)) + o(|β L (s + ∆s) − β L (s)|) (1) η i (β B (T)) = η i (β L (s)) + ∂η i ∂β (β L (s))(β B (T) − β L (s)) + o(|β B (T) − β L (s)|) (2)
  • 1